Contraindications and Interactions with Slynd (Drospirenone)

Introduction to Contraindications

The combination of Slynd (drospirenone) with tranexamic acid is contraindicated due to increased thrombotic risk, as listed in prescribing guidelines by the American Academy of Dermatology 1
Drospirenone carries risks of arterial thromboembolism, deep vein thrombosis, and thrombotic stroke, contributing to the contraindication 1

Tranexamic acid inhibits fibrinolysis, potentially increasing thrombotic tendency, especially when combined with drospirenone 2, 3
The combination of drospirenone and tranexamic acid may create a synergistic prothrombotic effect, significantly elevating the risk of thromboembolic events 1, 2, 3

The Association of Anaesthetists guidelines note that tranexamic acid should be used with caution in patients on oral contraceptive pills, such as those containing drospirenone, due to the risk of thrombosis 3
The American Academy of Dermatology recommends avoiding the combination of Slynd (drospirenone) and tranexamic acid due to increased thrombotic risk 1

For patients requiring both hormonal contraception and management of heavy bleeding, consider alternative hormonal contraceptives with lower thrombotic risk profiles or non-hormonal methods for managing heavy menstrual bleeding 1
Patients with additional risk factors for thrombosis face even greater risks with the combination of Slynd and tranexamic acid 1
If the combination must be used, monitor closely for signs of thromboembolism and consider prophylactic anticoagulation if appropriate 3